Literature DB >> 3263976

[99mTc]-HM-PAO SPECT in Parkinson's disease.

G Pizzolato1, M Dam, N Borsato, B Saitta, C Da Col, N Perlotto, P Zanco, G Ferlin, L Battistin.   

Abstract

Thirty-six patients affected by Parkinson's disease were studied using single photon emission computed tomography (SPECT) and [99mTc]-HM-PAO as a tracer. The scanning procedure was performed 16-24 h after discontinuation of specific therapy. Tracer activity ratios were determined in 10 pairs of cerebellar, cortical, and subcortical regions. Data were compared with those of 10 age-matched controls. Most of the regions examined did not show any relevant change between parkinsonian and control subjects. Notably, mean activity in striatal regions were similar in the two groups. Increased activity in caudate-putamen was found in patients who were on chronic DOPA therapy. Side-to-side asymmetries in the basal ganglia increased with the severity of the disease. Significant reductions of tracer uptake, from control values, were observed bilaterally in the parietal cortex. These deficits were more pronounced in patients with mental deterioration and in subjects who had been chronically treated with anticholinergic drugs. Parietal perfusion deficits in parkinsonian patients resemble those described in Alzheimer's dementia. These findings suggest that the heterogeneous alterations of regional cerebral blood flow (rCBF) in parkinsonian patients reflect the multifactorial pathophysiology of the disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263976     DOI: 10.1038/jcbfm.1988.39

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  7 in total

1.  A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.

Authors:  M O Habert; U Spampinato; J L Mas; M L Piketty; M C Bourdel; J de Recondo; P Rondot; S Askienazy
Journal:  Eur J Nucl Med       Date:  1991

2.  Regional CBF changes in Parkinson's disease: a correlation with motor dysfunction.

Authors:  Jung-Lung Hsu; Tzyy-Ping Jung; Chien-Yeh Hsu; Wei-Chih Hsu; Yen-Kung Chen; Jeng-Ren Duann; Han-Cheng Wang; Scott Makeig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-17       Impact factor: 9.236

3.  Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization.

Authors:  S J Wang; R S Liu; H C Liu; K N Lin; D E Shan; K K Liao; J L Fuh; L S Lee
Journal:  Eur J Nucl Med       Date:  1993-04

4.  HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.

Authors:  H S Markus; D C Costa; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

5.  HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment.

Authors:  Sven E Pålhagen; Stefan Ekberg; Jan Wålinder; Ann-Kathrine Granérus; Göran Granerus
Journal:  J Neurol       Date:  2009-05-10       Impact factor: 4.849

6.  Three-dimensional surface display of brain perfusion with 123I-IMP in Parkinson's disease.

Authors:  H Tachibana; K Kawabata; Y Tomino; M Sugita; M Fukuchi
Journal:  Neuroradiology       Date:  1994-05       Impact factor: 2.804

7.  Quantitative study of 18F-(+)DTBZ image: comparison of PET template-based and MRI based image analysis.

Authors:  Hsu Jung Lung; Yi-Hsin Weng; Ming-Ching Wen; Ing-Tsung Hsiao; Kun-Ju Lin
Journal:  Sci Rep       Date:  2018-10-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.